Susanna Naggie
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Susanna Naggie has a total of 732 co-authors. Here are the top co-authors by number of shared publications:
Mark Sulkowski
Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine , Baltimore, MD
21 shared publicationsDushyantha Jayaweera
Department of Medicine, Miller School of Medicine, University of Miami, Miami, FL
15 shared publicationsMario Castro
Division of Pulmonary, Critical Care and Sleep Medicine, University of Kansas Medical Center, Kansas City, KS
15 shared publicationsFlorence Thicklin
Stakeholder Advisory Committee, Pittsburgh, PA
13 shared publicationsKathleen McTigue
Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA
13 shared publicationsNina Gentile
Department of Emergency Medicine, Lewis Katz School of Medicine at Temple University, Philadelphia, PA
13 shared publications
Latest Publications
- Open Access
- 6 November 2026
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
Simple Adiposity Measures Discriminate MASLD by Transient Elastography in People with HIV: Results from a US Multicenter Cohort
Background: 40% of people with HIV (PWH) have metabolic dysfunction-associated steatotic liver disease (MASLD), but simple clinical tools for risk stratification do not exist. We evaluated whether adiposity indices are associated with MASLD in PWH and whether performance varies by race or ethnicity. Methods: We examined PWH from a prospective, cross-sectional study conducted by the NIDDK-funded HIV NASH CRN. Participants had suppressed HIV-1 RNA and underwent vibration controlled transient elastography and anthropometric measurements. The primary outcome was MASLD, defined as controlled attenuation parameter (CAP) ≥263 dB/m with ≥1 cardiometabolic risk factor without heavy alcohol use or viral hepatitis. Adiposity indices included waist circumference (WC), body mass index (BMI), waist-to-height ratio (WHtR), body roundness index (BRI), relative fat mass (RFM), visceral adiposity index (VAI), and waist-to-hip ratio (WHR). Results: Among 990 PWH, 445 (44.9%) had MASLD. All adiposity indices were strongly associated with MASLD (p<0.001). Several adiposity indices had good discrimination for MASLD in the overall cohort, including WC (AUC 0.79, 95% CI 0.76-0.81), WHtR (0.77 [0.74-0.80]), BRI (0.77 [0.74-0.80]), and BMI (0.75 [0.72-0.78]). WC, RFM, WHtR, and BRI had significant interactions with race (interaction p<0.05). Adiposity indices overall performed better in Black and Hispanic PWH compared to White PWH. Conclusions: In PWH, adiposity indices were strongly associated with MASLD, though their discriminatory ability varied by race and ethnicity. Simple anthropometric indices may provide practical tools for MASLD risk assessment that could be tailored by race and ethnicity.
- 6 November 2026
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
Open AccessSimple Adiposity Measures Discriminate MASLD by Transient Elastography in People with HIV: Results from a US Multicenter Cohort
Background: 40% of people with HIV (PWH) have metabolic dysfunction-associated steatotic liver disease (MASLD), but simple clinical tools for risk stratification do not exist. We evaluated whether adiposity indices are associated with MASLD in PWH and whether performance varies by race or ethnicity. Methods: We examined PWH from a prospective, cross-sectional study conducted by the NIDDK-funded HIV NASH CRN. Participants had suppressed HIV-1 RNA and underwent vibration controlled transient elastography and anthropometric measurements. The primary outcome was MASLD, defined as controlled attenuation parameter (CAP) ≥263 dB/m with ≥1 cardiometabolic risk factor without heavy alcohol use or viral hepatitis. Adiposity indices included waist circumference (WC), body mass index (BMI), waist-to-height ratio (WHtR), body roundness index (BRI), relative fat mass (RFM), visceral adiposity index (VAI), and waist-to-hip ratio (WHR). Results: Among 990 PWH, 445 (44.9%) had MASLD. All adiposity indices were strongly associated with MASLD (p<0.001). Several adiposity indices had good discrimination for MASLD in the overall cohort, including WC (AUC 0.79, 95% CI 0.76-0.81), WHtR (0.77 [0.74-0.80]), BRI (0.77 [0.74-0.80]), and BMI (0.75 [0.72-0.78]). WC, RFM, WHtR, and BRI had significant interactions with race (interaction p<0.05). Adiposity indices overall performed better in Black and Hispanic PWH compared to White PWH. Conclusions: In PWH, adiposity indices were strongly associated with MASLD, though their discriminatory ability varied by race and ethnicity. Simple anthropometric indices may provide practical tools for MASLD risk assessment that could be tailored by race and ethnicity.
- Open Access
- 4 June 2026
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
Metformin on the Presence of COVID-19 Symptoms 6 Months After Infection: The ACTIV-6 Randomized Clinical Trial
Background: We conducted a quadruple-blinded, randomized, placebo-controlled trial of metformin for treating acute SARS-CoV-2 infection to prevent long COVID symptoms in low-risk adults. Methods: The ACTIV-6 platform evaluated repurposed medications for mild to moderate COVID-19. Between 19 September 2023 and 1 May 2024, 2983 outpatient adults ≥30 years with confirmed SARS-CoV-2 infection and ≥2 COVID-19 symptoms were included within 7 days of symptom onset from 90 sites. Participants were randomized to metformin or placebo for 14 days. Postacute sequelae of SARS-CoV-2 or death (PASCD) was ascertained by asking whether participants had symptoms they attributed to COVID-19 on day 180. Secondary outcomes included clinician-diagnosed long COVID. Results: The median age was 47 years (interquartile range 38–57); 63% were female; 47% were Hispanic/Latino; 83% reported ≥1 prior COVID-19 infections or ≥2 SARS-CoV-2 vaccines. There were no deaths. Overall, 96 (3.2%) reported COVID-19 symptoms on day 90, 101 (3.4%) on day 120, and 79 (2.6%) on day 180. The adjusted risk of symptoms on day 180 was 0.8 percentage points lower with metformin (95% credible interval [CrI] −2.2 to 0.6) with a posterior probability of efficacy (PPE) for preventing symptoms of 0.83, risk ratio 0.79 (95% CrI 0.474 to 1.230). Compared with placebo, the risk of clinician-diagnosed long COVID was 0.7 percentage points lower with metformin (95% CrI −1.5 to 0.1); PPE 0.96; risk ratio 0.495 (95% CrI 0.155–0.995). Conclusions: In low-risk adults, most with prior immunity, metformin did not exceed the efficacy threshold of 0.975 for PASC. Metformin reduced the risk of clinician-diagnosed long COVID. Clinical Trail Registration: ClinicalTrials.gov (NCT04885530).
- 4 June 2026
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
Open AccessMetformin on the Presence of COVID-19 Symptoms 6 Months After Infection: The ACTIV-6 Randomized Clinical Trial
Background: We conducted a quadruple-blinded, randomized, placebo-controlled trial of metformin for treating acute SARS-CoV-2 infection to prevent long COVID symptoms in low-risk adults. Methods: The ACTIV-6 platform evaluated repurposed medications for mild to moderate COVID-19. Between 19 September 2023 and 1 May 2024, 2983 outpatient adults ≥30 years with confirmed SARS-CoV-2 infection and ≥2 COVID-19 symptoms were included within 7 days of symptom onset from 90 sites. Participants were randomized to metformin or placebo for 14 days. Postacute sequelae of SARS-CoV-2 or death (PASCD) was ascertained by asking whether participants had symptoms they attributed to COVID-19 on day 180. Secondary outcomes included clinician-diagnosed long COVID. Results: The median age was 47 years (interquartile range 38–57); 63% were female; 47% were Hispanic/Latino; 83% reported ≥1 prior COVID-19 infections or ≥2 SARS-CoV-2 vaccines. There were no deaths. Overall, 96 (3.2%) reported COVID-19 symptoms on day 90, 101 (3.4%) on day 120, and 79 (2.6%) on day 180. The adjusted risk of symptoms on day 180 was 0.8 percentage points lower with metformin (95% credible interval [CrI] −2.2 to 0.6) with a posterior probability of efficacy (PPE) for preventing symptoms of 0.83, risk ratio 0.79 (95% CrI 0.474 to 1.230). Compared with placebo, the risk of clinician-diagnosed long COVID was 0.7 percentage points lower with metformin (95% CrI −1.5 to 0.1); PPE 0.96; risk ratio 0.495 (95% CrI 0.155–0.995). Conclusions: In low-risk adults, most with prior immunity, metformin did not exceed the efficacy threshold of 0.975 for PASC. Metformin reduced the risk of clinician-diagnosed long COVID. Clinical Trail Registration: ClinicalTrials.gov (NCT04885530).
- Open Access
- 28 April 2026
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 13 (5)
Non-Hispanic Black Persons With HIV Have a Lower Risk of Metabolic Dysfunction–Associated Steatotic Liver Disease and Clinically Significant Fibrosis Compared to Non-Hispanic White and Hispanic Individuals
Background: Metabolic dysfunction–associated steatotic liver disease (MASLD) is a major cause of liver-related morbidity and mortality among people with human immunodeficiency virus (PWH). We aimed to determine the prevalence of MASLD and clinically significant fibrosis among PWH and investigate if racial and ethnic differences exist after adjustment for clinical risk factors and PNPLA3 genotype. Methods: This cross-sectional analysis included adult PWH prospectively enrolled in 2 US multicenter studies from 2018 to 2023. MASLD was defined as a controlled attenuation parameter (CAP) score ≥263 dB/m with at least 1 cardiometabolic risk factor and clinically significant fibrosis as a liver stiffness measurement ≥8 kPa upon vibration-controlled transient elastography. Multivariable logistic regression analysis was performed to examine the association of race/ethnicity with the presence of MASLD and clinically significant fibrosis, adjusting for clinical risk factors and PNPLA3 genotype. Results: Of the 996 participants, the mean age was 53.9 years (standard deviation, 12 years) and 72% were male. The prevalence of MASLD and clinically significant fibrosis were 49% and 14%, respectively. Non-Hispanic Black (NHB) persons had the lowest prevalence of MASLD (43%) compared to non-Hispanic White (NHW) (53%) and Hispanic individuals (60%) (P < .001). Similarly, NHB persons had the lowest prevalence of clinically significant fibrosis (12%) compared to NHW (20%) and Hispanic individuals (13%) (P = .005). After adjusting for clinical risk factors and PNPLA3 genotype, NHB had a lower odds of MASLD (odds ratio [OR], 0.39 [95% confidence interval {CI}, .23–.66]) and clinically significant fibrosis (OR, 0.38 [95% CI, .20–.71]) compared to NHW persons. Conclusions: NHB PWH have a lower risk of MASLD and clinically significant fibrosis compared to NHW and Hispanic individuals, even after controlling for clinical risk factors and PNPLA3 genotype.
- 28 April 2026
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 13 (5)
Open AccessNon-Hispanic Black Persons With HIV Have a Lower Risk of Metabolic Dysfunction–Associated Steatotic Liver Disease and Clinically Significant Fibrosis Compared to Non-Hispanic White and Hispanic Individuals
Background: Metabolic dysfunction–associated steatotic liver disease (MASLD) is a major cause of liver-related morbidity and mortality among people with human immunodeficiency virus (PWH). We aimed to determine the prevalence of MASLD and clinically significant fibrosis among PWH and investigate if racial and ethnic differences exist after adjustment for clinical risk factors and PNPLA3 genotype. Methods: This cross-sectional analysis included adult PWH prospectively enrolled in 2 US multicenter studies from 2018 to 2023. MASLD was defined as a controlled attenuation parameter (CAP) score ≥263 dB/m with at least 1 cardiometabolic risk factor and clinically significant fibrosis as a liver stiffness measurement ≥8 kPa upon vibration-controlled transient elastography. Multivariable logistic regression analysis was performed to examine the association of race/ethnicity with the presence of MASLD and clinically significant fibrosis, adjusting for clinical risk factors and PNPLA3 genotype. Results: Of the 996 participants, the mean age was 53.9 years (standard deviation, 12 years) and 72% were male. The prevalence of MASLD and clinically significant fibrosis were 49% and 14%, respectively. Non-Hispanic Black (NHB) persons had the lowest prevalence of MASLD (43%) compared to non-Hispanic White (NHW) (53%) and Hispanic individuals (60%) (P < .001). Similarly, NHB persons had the lowest prevalence of clinically significant fibrosis (12%) compared to NHW (20%) and Hispanic individuals (13%) (P = .005). After adjusting for clinical risk factors and PNPLA3 genotype, NHB had a lower odds of MASLD (odds ratio [OR], 0.39 [95% confidence interval {CI}, .23–.66]) and clinically significant fibrosis (OR, 0.38 [95% CI, .20–.71]) compared to NHW persons. Conclusions: NHB PWH have a lower risk of MASLD and clinically significant fibrosis compared to NHW and Hispanic individuals, even after controlling for clinical risk factors and PNPLA3 genotype.
- Top Cited Papers
- 4 November 2025
- Published by Wolters Kluwer Health in Hepatology
- Vol. 83 (4) , 974-997
AASLD IDSA Practice Guideline on treatment of chronic hepatitis B
Background and Aims: Accumulating data related to prevention, surveillance and treatment of chronic hepatitis B (CHB) provided the impetus for this updated guideline, using the Grading of Recommendation Assessment, Development and Evaluation (GRADE) approach. Methods: The guideline was developed in compliance with the National Academy of Medicine standards. The guideline panel developed structured questions following the Population, Intervention Comparison, Outcomes (PICO) framework. The panel addressed 6 PICO questions covering prevention (maternal to infant transmission and horizontal transmission), surveillance for liver cancer (among hepatitis B surface antigen positive (HBsAg) persons co-infected with hepatitis C virus, hepatitis D virus and/or human immunodeficiency viruses and after HBsAg loss) and treatment (HBsAg positive persons in immune-tolerant or indeterminate phases as well as withdrawal of antiviral therapy), providing evidence-based recommendations on these topics. Four systematic reviews of the literature were conducted, and two existing systematic reviews were utilized to support the recommendations in this practice guideline. Conclusions: This evidence-based guideline provides updated recommendations to optimize the care of persons with CHB.
- 4 November 2025
- Published by Wolters Kluwer Health in Hepatology
- Vol. 83 (4) , 974-997
Top Cited PapersAASLD IDSA Practice Guideline on treatment of chronic hepatitis B
Background and Aims: Accumulating data related to prevention, surveillance and treatment of chronic hepatitis B (CHB) provided the impetus for this updated guideline, using the Grading of Recommendation Assessment, Development and Evaluation (GRADE) approach. Methods: The guideline was developed in compliance with the National Academy of Medicine standards. The guideline panel developed structured questions following the Population, Intervention Comparison, Outcomes (PICO) framework. The panel addressed 6 PICO questions covering prevention (maternal to infant transmission and horizontal transmission), surveillance for liver cancer (among hepatitis B surface antigen positive (HBsAg) persons co-infected with hepatitis C virus, hepatitis D virus and/or human immunodeficiency viruses and after HBsAg loss) and treatment (HBsAg positive persons in immune-tolerant or indeterminate phases as well as withdrawal of antiviral therapy), providing evidence-based recommendations on these topics. Four systematic reviews of the literature were conducted, and two existing systematic reviews were utilized to support the recommendations in this practice guideline. Conclusions: This evidence-based guideline provides updated recommendations to optimize the care of persons with CHB.
- Open Access
- 9 September 2025
- Published by Cambridge University Press (CUP) in Journal of Clinical and Translational Science
- Vol. 9 (1) , e221
A qualitative evaluation of the Research Equity and Diversity Initiative’s (READI) research support voucher program and its community engagement support
The Duke Research Equity and Diversity Initiative (READI) was established in 2021 to engage Durham and surrounding communities in clinical research and build capacity to promote equitable access to research participation. Within READI, a voucher program was launched with the goals of increasing diverse participation in clinical research, improving community-partnered research, and enhancing community engagement. The vouchers leveraged a stand-alone, community-centered, outpatient research clinic, the Duke Research at Pickett (R@P) facility, which was originally opened to support COVID-19 trials. A formative evaluation of the voucher program was conducted with 3 voucher-awarded teams, READI personnel, and R@P staff. Data included 18 semi-structured interviews (n = 14) over two timepoints (Spring 2023, 2024). A rapid response analysis approach was used. Data indicate that READI voucher-awarded services were useful for voucher teams, with value for supporting community-engaged efforts, making research participation accessible, creating a community-centered and streamlined service facility, and personnel development benefits. Communication and flexibility of support services facilitated program implementation. Challenges occurred in service utilization logistics and incorporating community engagement into research support services. Ultimately, we find that a research support program with embedded community engagement support is feasible; this type of support can be integral in normalizing community-engaged research.
- 9 September 2025
- Published by Cambridge University Press (CUP) in Journal of Clinical and Translational Science
- Vol. 9 (1) , e221
Open AccessA qualitative evaluation of the Research Equity and Diversity Initiative’s (READI) research support voucher program and its community engagement support
The Duke Research Equity and Diversity Initiative (READI) was established in 2021 to engage Durham and surrounding communities in clinical research and build capacity to promote equitable access to research participation. Within READI, a voucher program was launched with the goals of increasing diverse participation in clinical research, improving community-partnered research, and enhancing community engagement. The vouchers leveraged a stand-alone, community-centered, outpatient research clinic, the Duke Research at Pickett (R@P) facility, which was originally opened to support COVID-19 trials. A formative evaluation of the voucher program was conducted with 3 voucher-awarded teams, READI personnel, and R@P staff. Data included 18 semi-structured interviews (n = 14) over two timepoints (Spring 2023, 2024). A rapid response analysis approach was used. Data indicate that READI voucher-awarded services were useful for voucher teams, with value for supporting community-engaged efforts, making research participation accessible, creating a community-centered and streamlined service facility, and personnel development benefits. Communication and flexibility of support services facilitated program implementation. Challenges occurred in service utilization logistics and incorporating community engagement into research support services. Ultimately, we find that a research support program with embedded community engagement support is feasible; this type of support can be integral in normalizing community-engaged research.
- 1 September 2025
- Published by American Medical Association (AMA) in JAMA Internal Medicine
- Vol. 185 (9) , 1092-1101
Metformin and Time to Sustained Recovery in Adults With COVID-19
Importance: The effect of metformin on reducing symptom duration among outpatient adults with COVID-19 has not been studied.Objective: To assess metformin compared with placebo for symptom resolution during acute infection with SARS-CoV-2.Design, Setting, and Participants: The Accelerating COVID-19 Therapeutic Interventions and Vaccines platform evaluated repurposed medications for mild to moderate COVID-19. Between September 19, 2023, and May 1, 2024, participants 30 years or older with confirmed SARS-CoV-2 infection and 2 or more COVID-19 symptoms for 7 days or less were included at 90 US sites.Interventions: Participants were randomized to receive metformin (titrated to 1500 mg, daily) or placebo for 14 days.Main Outcomes and Measures: The primary outcome was time to sustained recovery (3 consecutive days without COVID-19 symptoms) within 28 days of receiving the study drug. Secondary outcomes included time to clinic visit, emergency department (ED) visit, hospitalization, or death. Safety events of interest were hypoglycemia and lactic acidosis.Results: Among 2991 participants who were randomized and received study drug, the median age was 47 (IQR, 38-58) years; 1895 (63.4%) were female, 25 (0.8%) were American Indian of Alaska Native, 77 (2.6%) were Asian, 350 (11.7%) were Black, African American, or African, 1392 (46.5%) identified as Hispanic or Latino, 8 (0.3%) were Native Hawaiian or other Pacific Islander, 2395 (80.1%) were White, and 2044 (68.3%) reported 2 or more doses of a SARS-CoV-2 vaccine. Among 1443 (48.2%) participants who received metformin and 1548 (51.8%) who received placebo, differences in time to sustained recovery were not observed (adjusted hazard ratio, 0.96; 95% credible interval [CrI], 0.89-1.03; P for efficacy = .11). The median time to sustained recovery was 9 days (95% CI, 9-10) for metformin and 10 days (95% CI, 9-10) for placebo. No deaths were reported; 103 participants reported clinic visits, ED visits, or hospitalization: 54 in the metformin group and 49 in the placebo group (hazard ratio, 1.25; 95% CrI, 0.82-1.78; P for efficacy = .13). Overall, 35 (1.2%) reported ED visits or hospitalization (1.1% in the metformin and 1.3% in the placebo group). Seven participants who received metformin and 3 who received placebo experienced a serious adverse event over 180 days. There were 4 episodes of participant-reported hypoglycemia in the placebo group and 2 in the metformin group.Conclusions and Relevance: In this randomized clinical trial, metformin was not shown to shorten the time to symptom resolution in low-risk adults with COVID-19. The median days to symptom resolution was numerically but not significantly lower for metformin. Safety was not a limitation in the study population.Trial Registration: ClinicalTrials.gov Identifier: NCT04885530
- 1 September 2025
- Published by American Medical Association (AMA) in JAMA Internal Medicine
- Vol. 185 (9) , 1092-1101
Metformin and Time to Sustained Recovery in Adults With COVID-19
Importance: The effect of metformin on reducing symptom duration among outpatient adults with COVID-19 has not been studied.Objective: To assess metformin compared with placebo for symptom resolution during acute infection with SARS-CoV-2.Design, Setting, and Participants: The Accelerating COVID-19 Therapeutic Interventions and Vaccines platform evaluated repurposed medications for mild to moderate COVID-19. Between September 19, 2023, and May 1, 2024, participants 30 years or older with confirmed SARS-CoV-2 infection and 2 or more COVID-19 symptoms for 7 days or less were included at 90 US sites.Interventions: Participants were randomized to receive metformin (titrated to 1500 mg, daily) or placebo for 14 days.Main Outcomes and Measures: The primary outcome was time to sustained recovery (3 consecutive days without COVID-19 symptoms) within 28 days of receiving the study drug. Secondary outcomes included time to clinic visit, emergency department (ED) visit, hospitalization, or death. Safety events of interest were hypoglycemia and lactic acidosis.Results: Among 2991 participants who were randomized and received study drug, the median age was 47 (IQR, 38-58) years; 1895 (63.4%) were female, 25 (0.8%) were American Indian of Alaska Native, 77 (2.6%) were Asian, 350 (11.7%) were Black, African American, or African, 1392 (46.5%) identified as Hispanic or Latino, 8 (0.3%) were Native Hawaiian or other Pacific Islander, 2395 (80.1%) were White, and 2044 (68.3%) reported 2 or more doses of a SARS-CoV-2 vaccine. Among 1443 (48.2%) participants who received metformin and 1548 (51.8%) who received placebo, differences in time to sustained recovery were not observed (adjusted hazard ratio, 0.96; 95% credible interval [CrI], 0.89-1.03; P for efficacy = .11). The median time to sustained recovery was 9 days (95% CI, 9-10) for metformin and 10 days (95% CI, 9-10) for placebo. No deaths were reported; 103 participants reported clinic visits, ED visits, or hospitalization: 54 in the metformin group and 49 in the placebo group (hazard ratio, 1.25; 95% CrI, 0.82-1.78; P for efficacy = .13). Overall, 35 (1.2%) reported ED visits or hospitalization (1.1% in the metformin and 1.3% in the placebo group). Seven participants who received metformin and 3 who received placebo experienced a serious adverse event over 180 days. There were 4 episodes of participant-reported hypoglycemia in the placebo group and 2 in the metformin group.Conclusions and Relevance: In this randomized clinical trial, metformin was not shown to shorten the time to symptom resolution in low-risk adults with COVID-19. The median days to symptom resolution was numerically but not significantly lower for metformin. Safety was not a limitation in the study population.Trial Registration: ClinicalTrials.gov Identifier: NCT04885530
- Open Access
Metformin on the Presence of COVID-19 Symptoms Over 6 Months: The ACTIV-6 Randomized Clinical Trial
Background The effect of metformin on preventing long-term COVID-19 symptoms among low-risk adults has not been studied. The objective of this study was to Assess metformin compared with placebo during acute SARS-CoV-2 infection on the presence of COVID-19 symptoms 180 days later. Methods The ACTIV-6 platform evaluated repurposed medications for mild to moderate COVID-19. Between September 19, 2023 and May 1, 2024, 2983 outpatient adults ≥30 years with confirmed SARS-CoV-2 infection and ≥2 COVID-19 symptoms for ≤7 days were included from 90 sites. Participants were randomized to metformin (titrated to 1500 mg daily) or placebo for 14 days. Post-acute sequelae of SARS-CoV-2 or death (PASCD) was ascertained by asking whether participants had symptoms they attributed to COVID-19 on day 180. Secondary outcomes included clinician diagnosis of long COVID. For the primary outcome, the single-sided threshold for efficacy was 0.975. Results Among 2983 participants, the median age was 47 years (interquartile range [IQR] 38–57); 63% were female; 47% Hispanic/Latino; 83% reported ≥1 prior COVID-19 infections or SARS-CoV-2 vaccines. There were no deaths. Overall, 96 (3.2%) reported COVID-19 symptoms on day 90, 101 (3.4%) on day 120, and 79 (2.6%) on day 180. The covariate-adjusted risk of PASCD on day 180 was lower in the metformin group (−0.008; 95% credible interval [CrI] −0.022 to 0.006; posterior probability of efficacy [PPE] 0.83), compared with the placebo group with an adjusted risk ratio of 0.79 (95% CrI 0.474 to 1.230). The risk of clinician diagnosis of long COVID (secondary outcome) on day 180 was lower in the metformin group (−0.007; 95% CrI −0.015 to 0.001; PPE 0.96), with a relative risk of 0.495 (95% CrI 0.155 to 0.995). Conclusions The posterior probability of efficacy for metformin preventing the primary endpoint did not exceed the prespecified threshold of 0.975 for declaring efficacy. Secondary outcomes were numerically better with metformin. Trial Registration ClinicalTrials.gov (NCT04885530).
Open AccessMetformin on the Presence of COVID-19 Symptoms Over 6 Months: The ACTIV-6 Randomized Clinical Trial
Background The effect of metformin on preventing long-term COVID-19 symptoms among low-risk adults has not been studied. The objective of this study was to Assess metformin compared with placebo during acute SARS-CoV-2 infection on the presence of COVID-19 symptoms 180 days later. Methods The ACTIV-6 platform evaluated repurposed medications for mild to moderate COVID-19. Between September 19, 2023 and May 1, 2024, 2983 outpatient adults ≥30 years with confirmed SARS-CoV-2 infection and ≥2 COVID-19 symptoms for ≤7 days were included from 90 sites. Participants were randomized to metformin (titrated to 1500 mg daily) or placebo for 14 days. Post-acute sequelae of SARS-CoV-2 or death (PASCD) was ascertained by asking whether participants had symptoms they attributed to COVID-19 on day 180. Secondary outcomes included clinician diagnosis of long COVID. For the primary outcome, the single-sided threshold for efficacy was 0.975. Results Among 2983 participants, the median age was 47 years (interquartile range [IQR] 38–57); 63% were female; 47% Hispanic/Latino; 83% reported ≥1 prior COVID-19 infections or SARS-CoV-2 vaccines. There were no deaths. Overall, 96 (3.2%) reported COVID-19 symptoms on day 90, 101 (3.4%) on day 120, and 79 (2.6%) on day 180. The covariate-adjusted risk of PASCD on day 180 was lower in the metformin group (−0.008; 95% credible interval [CrI] −0.022 to 0.006; posterior probability of efficacy [PPE] 0.83), compared with the placebo group with an adjusted risk ratio of 0.79 (95% CrI 0.474 to 1.230). The risk of clinician diagnosis of long COVID (secondary outcome) on day 180 was lower in the metformin group (−0.007; 95% CrI −0.015 to 0.001; PPE 0.96), with a relative risk of 0.495 (95% CrI 0.155 to 0.995). Conclusions The posterior probability of efficacy for metformin preventing the primary endpoint did not exceed the prespecified threshold of 0.975 for declaring efficacy. Secondary outcomes were numerically better with metformin. Trial Registration ClinicalTrials.gov (NCT04885530).
- 30 July 2025
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 81 (6) , 1083-1090
Short Course Therapy With Glecaprevir/Pibrentasvir for Early Hepatitis C Virus Infection: PURGE-C
Background: Shorter treatment courses for early hepatitis C virus (HCV) infection could simplify treatment approaches, particularly in key populations. Methods: PURGE-C (A5380) was a single-arm, multicenter trial evaluating the treatment of early HCV (primary or reinfection) with 4 weeks of glecaprevir/pibrentasvir (G/P). Early HCV was defined as new detectable HCV RNA or alanine aminotransferase (ALT) elevation within 24 weeks of study entry. The primary endpoint was sustained virologic response (SVR) 12 weeks after prescribed treatment completion (SVR12). Re-treatment outcomes were also collected. Results: Forty-five participants (98% male, 51% White, 31% Hispanic, median age 36 years, 51% with human immunodeficiency virus [HIV], 27% self-reported injecting drugs) were enrolled from the United States and Brazil between November 2019 and January 2023. Median time from HCV diagnosis to entry was 31 days (Q1–Q3: 15–49). Median baseline HCV RNA was 5.3 log10 IU/mL (Q1–Q3: 3.3–6.0) and ALT 146 U/L (min–max: 22–3866). Overall, 38 of 45 (84%) participants (90% confidence interval [CI]: 74%–91%) achieved SVR12. All 4 participants who were retreated and had outcome data achieved SVR12. Conclusions: In this population with elevated risk of onward HCV transmission, 84% were cured with 4 weeks of G/P. Failing this short-course treatment did not compromise retreatment. This study suggests that people with early HCV infection can achieve moderately high cure rates with abbreviated courses of direct-acting antivirals (DAA). Simplified approaches to treatment are critical for HCV elimination and are particularly relevant for populations difficult to retain in care. Clinical Trial Registration: NCT04042740.
- 30 July 2025
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 81 (6) , 1083-1090
Short Course Therapy With Glecaprevir/Pibrentasvir for Early Hepatitis C Virus Infection: PURGE-C
Background: Shorter treatment courses for early hepatitis C virus (HCV) infection could simplify treatment approaches, particularly in key populations. Methods: PURGE-C (A5380) was a single-arm, multicenter trial evaluating the treatment of early HCV (primary or reinfection) with 4 weeks of glecaprevir/pibrentasvir (G/P). Early HCV was defined as new detectable HCV RNA or alanine aminotransferase (ALT) elevation within 24 weeks of study entry. The primary endpoint was sustained virologic response (SVR) 12 weeks after prescribed treatment completion (SVR12). Re-treatment outcomes were also collected. Results: Forty-five participants (98% male, 51% White, 31% Hispanic, median age 36 years, 51% with human immunodeficiency virus [HIV], 27% self-reported injecting drugs) were enrolled from the United States and Brazil between November 2019 and January 2023. Median time from HCV diagnosis to entry was 31 days (Q1–Q3: 15–49). Median baseline HCV RNA was 5.3 log10 IU/mL (Q1–Q3: 3.3–6.0) and ALT 146 U/L (min–max: 22–3866). Overall, 38 of 45 (84%) participants (90% confidence interval [CI]: 74%–91%) achieved SVR12. All 4 participants who were retreated and had outcome data achieved SVR12. Conclusions: In this population with elevated risk of onward HCV transmission, 84% were cured with 4 weeks of G/P. Failing this short-course treatment did not compromise retreatment. This study suggests that people with early HCV infection can achieve moderately high cure rates with abbreviated courses of direct-acting antivirals (DAA). Simplified approaches to treatment are critical for HCV elimination and are particularly relevant for populations difficult to retain in care. Clinical Trial Registration: NCT04042740.
- 23 July 2025
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 81 (5) , e470-e471
Take It Off the Back Burner—Missed Opportunities to Treat Hepatitis C Virus Inpatients
- 23 July 2025
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 81 (5) , e470-e471
Take It Off the Back Burner—Missed Opportunities to Treat Hepatitis C Virus Inpatients
- Open Access
- 7 July 2025
- Published by Cambridge University Press (CUP) in Journal of Clinical and Translational Science
- Vol. 9 (1) , e156
The research equity and diversity initiative (READI): Changing the face of clinical research through community outreach and engagement
Current evidence underscores a need to transform how we do clinical research, shifting from academic-driven priorities to co-led community partnership focused programs, accessible and relevant career pathway programs that expand opportunities for career development, and design of trainings and practices to develop cultural competence among research teams. Failures of equitable research translation contribute to health disparities. Drivers of this failed translation include lack of diversity in both researchers and participants, lack of alignment between research institutions and the communities they serve, and lack of attention to structural sources of inequity and drivers of mistrust for science and research. The Duke University Research Equity and Diversity Initiative (READI) is a program designed to better align clinical research programs with community health priorities through community engagement. Organized around three specific aims, READI-supported programs targeting increased workforce diversity, workforce training in community engagement and cultural competence, inclusive research engagement principles, and development of trustworthy partnerships.
- 7 July 2025
- Published by Cambridge University Press (CUP) in Journal of Clinical and Translational Science
- Vol. 9 (1) , e156
Open AccessThe research equity and diversity initiative (READI): Changing the face of clinical research through community outreach and engagement
Current evidence underscores a need to transform how we do clinical research, shifting from academic-driven priorities to co-led community partnership focused programs, accessible and relevant career pathway programs that expand opportunities for career development, and design of trainings and practices to develop cultural competence among research teams. Failures of equitable research translation contribute to health disparities. Drivers of this failed translation include lack of diversity in both researchers and participants, lack of alignment between research institutions and the communities they serve, and lack of attention to structural sources of inequity and drivers of mistrust for science and research. The Duke University Research Equity and Diversity Initiative (READI) is a program designed to better align clinical research programs with community health priorities through community engagement. Organized around three specific aims, READI-supported programs targeting increased workforce diversity, workforce training in community engagement and cultural competence, inclusive research engagement principles, and development of trustworthy partnerships.